基于 HLA-Ig 的“乐高式系统”用于 T 细胞监测、调节和扩增的概述。
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
机构信息
Department of Pathology, Johns Hopkins University, School of Medicine, Ross Research Bldg Room 644 B, Baltimore, MD 21205-2196, USA.
出版信息
Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z.
Abstract
Recent advances in molecular medicine have shown that soluble MHC-multimers can be valuable tools for both analysis and modulation of antigen-specific immune responses in vitro and in vivo. In this review, we describe the use of dimeric human and mouse major histocompatibility complexes, MHC-Ig, as part of an artificial Antigen-Presenting Cell (aAPC). MHC-Ig-based aAPC and its derivatives represent an exciting new platform technology for measuring and manipulating immune responses in vitro as well as in vivo. This new technology has the potential to help overcome many of the obstacles associated with limitations in current antigen-specific approaches of immunotherapy for the treatment of cancer, infectious diseases and autoimmunity.
摘要
近年来，分子医学的进展表明，可溶性 MHC 多聚体可以成为体外和体内分析和调节抗原特异性免疫反应的有价值的工具。在这篇综述中，我们描述了二聚体人源和鼠源主要组织相容性复合物（MHC-Ig）作为人工抗原呈递细胞（aAPC）的一部分的用途。基于 MHC-Ig 的 aAPC 及其衍生物代表了一种令人兴奋的新技术平台，用于测量和操纵体外和体内的免疫反应。这项新技术有可能帮助克服当前癌症、传染病和自身免疫性疾病免疫治疗中与抗原特异性方法相关的许多限制。
相似文献
1
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.基于 HLA-Ig 的“乐高式系统”用于 T 细胞监测、调节和扩增的概述。
Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z.
2
HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.基于HLA-Ig的人工抗原呈递细胞：设定相互作用的条件
Clin Immunol. 2004 Mar;110(3):243-51. doi: 10.1016/j.clim.2003.11.014.
3
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.通过 HLA-Ig 包被的人工抗原呈递细胞进行抗原特异性细胞毒性 T 细胞的体外诱导和扩增。
Nat Med. 2003 May;9(5):619-24. doi: 10.1038/nm869. Epub 2003 Apr 21.
4
HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.基于HLA-Ig的人工抗原呈递细胞用于人细胞毒性T淋巴细胞的高效体外扩增。
J Vis Exp. 2011 Apr 11(50):2801. doi: 10.3791/2801.
5
Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.表达肽-β2-微球蛋白-主要组织相容性复合体的细胞是能够产生特异性T细胞的高效抗原呈递细胞。
Immunology. 2007 Sep;122(1):90-7. doi: 10.1111/j.1365-2567.2007.02616.x. Epub 2007 Apr 30.
6
In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).使用基于HLA-Ig的人工抗原呈递细胞（aAPC）扩增的肿瘤特异性T细胞的体内功能疗效。
Cancer Immunol Immunother. 2009 Feb;58(2):209-20. doi: 10.1007/s00262-008-0542-1. Epub 2008 Jun 18.
7
Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.通过CD1d1-Ig包被的人工抗原呈递细胞进行自然杀伤T细胞的体外诱导和扩增。
J Immunol Methods. 2009 Jul 31;346(1-2):38-44. doi: 10.1016/j.jim.2009.05.003. Epub 2009 May 14.
8
HLA-Class II Artificial Antigen Presenting Cells in CD4 T Cell-Based Immunotherapy.HLA-II 类人工抗原呈递细胞在基于 CD4 T 细胞的免疫治疗中的应用。
Front Immunol. 2019 May 17;10:1081. doi: 10.3389/fimmu.2019.01081. eCollection 2019.
9
Quality and quantity: new strategies to improve immunotherapy of cancer.质量与数量：改善癌症免疫疗法的新策略
Trends Mol Med. 2004 May;10(5):205-8. doi: 10.1016/j.molmed.2004.03.004.
10
Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.人工抗原呈递细胞在诱导抗原特异性细胞毒性 T 淋巴细胞方面优于树突状细胞。
Cell Immunol. 2018 Dec;334:78-86. doi: 10.1016/j.cellimm.2018.10.002. Epub 2018 Oct 23.
引用本文的文献
1
Ex vivo expansion and hydrogel-mediated in vivo delivery of tissue-resident memory T cells for immunotherapy.用于免疫治疗的组织驻留记忆T细胞的体外扩增及水凝胶介导的体内递送
Sci Adv. 2024 Dec 13;10(50):eadm7928. doi: 10.1126/sciadv.adm7928.
2
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.MediMer：一种多功能 DIY 肽受体 MHC Ⅰ类多聚体平台，用于肿瘤新抗原特异性 T 细胞检测。
Front Immunol. 2024 Jan 4;14:1294565. doi: 10.3389/fimmu.2023.1294565. eCollection 2023.
3
Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems.高度可定制的结冷胶纳米颗粒作为T细胞激活剂系统开发的平台。
Biomater Res. 2022 Sep 30;26(1):48. doi: 10.1186/s40824-022-00297-z.
4
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.用于增强癌症免疫疗法中抗原特异性 T 细胞扩增的生物材料。
Biomaterials. 2021 Jan;268:120584. doi: 10.1016/j.biomaterials.2020.120584. Epub 2020 Dec 5.
5
Review: Bioengineering strategies to probe T cell mechanobiology.综述：用于探究T细胞力学生物学的生物工程策略。
APL Bioeng. 2018 Mar 29;2(2):021501. doi: 10.1063/1.5006599. eCollection 2018 Jun.
6
Engineering Platforms for T Cell Modulation.工程化平台用于 T 细胞调控。
Int Rev Cell Mol Biol. 2018;341:277-362. doi: 10.1016/bs.ircmb.2018.06.003. Epub 2018 Jul 30.
7
Soluble MHC class I complexes for targeted immunotherapy.可溶性 MHC Ⅰ类复合物用于靶向免疫治疗。
Life Sci. 2018 Sep 15;209:255-258. doi: 10.1016/j.lfs.2018.08.023. Epub 2018 Aug 10.
8
Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.人工抗原呈递细胞和淋巴器官的生物工程。
Theranostics. 2017 Aug 17;7(14):3504-3516. doi: 10.7150/thno.19017. eCollection 2017.
9
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.基于T细胞的癌症免疫疗法中人工抗原呈递细胞的基础
J Immunol Res Ther. 2017;2(1):68-79. Epub 2017 Jun 26.
10
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth.双靶向纳米颗粒刺激免疫系统抑制肿瘤生长。
ACS Nano. 2017 Jun 27;11(6):5417-5429. doi: 10.1021/acsnano.6b08152. Epub 2017 Jun 7.
本文引用的文献
1
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.抗原特异性T淋巴细胞的表型分析。《科学》。1996年。第274卷：94 - 96页。
J Immunol. 2011 Jul 1;187(1):7-9.
2
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.体内给予人工抗原呈递细胞可激活低亲和性 T 细胞用于癌症治疗。
Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.
3
Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus.开发一种基于人工抗原呈递细胞的检测方法，用于检测全血中低频病毒特异性CD8(+) T细胞，并应用于麻疹病毒检测。
Clin Vaccine Immunol. 2009 Jul;16(7):1066-73. doi: 10.1128/CVI.00365-08. Epub 2009 Jun 3.
4
Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.通过CD1d1-Ig包被的人工抗原呈递细胞进行自然杀伤T细胞的体外诱导和扩增。
J Immunol Methods. 2009 Jul 31;346(1-2):38-44. doi: 10.1016/j.jim.2009.05.003. Epub 2009 May 14.
5
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.杀伤性人工抗原呈递细胞：一种清除特定T细胞的新策略。
Blood. 2008 Apr 1;111(7):3546-52. doi: 10.1182/blood-2007-09-113522. Epub 2007 Dec 20.
6
Altered macrophage differentiation and immune dysfunction in tumor development.肿瘤发生过程中巨噬细胞分化改变与免疫功能障碍
J Clin Invest. 2007 May;117(5):1155-66. doi: 10.1172/JCI31422.
7
Artificial antigen-presenting cells: artificial solutions for real diseases.人工抗原呈递细胞：针对实际疾病的人工解决方案。
Trends Mol Med. 2005 Sep;11(9):412-20. doi: 10.1016/j.molmed.2005.07.005.
8
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.体外扩增的人CD4+调节性自然杀伤T细胞抑制肿瘤抗原特异性细胞毒性T淋巴细胞的扩增。
Int Immunol. 2005 Sep;17(9):1143-55. doi: 10.1093/intimm/dxh292. Epub 2005 Jul 18.
9
Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.癌症患者注射负载α-半乳糖神经酰胺的成熟树突状细胞后NKT细胞和抗原特异性T细胞的持续扩增
J Exp Med. 2005 May 2;201(9):1503-17. doi: 10.1084/jem.20042592.
10
A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.一项针对晚期和复发性非小细胞肺癌患者的α-半乳糖神经酰胺（KRN7000）脉冲树突状细胞的I期研究。
Clin Cancer Res. 2005 Mar 1;11(5):1910-7. doi: 10.1158/1078-0432.CCR-04-1453.
Zotero 插件